Pfizer and BioNTech's COVID-19 vaccine demonstrates over 90% efficacy as hope builds for an early end to the pandem… https://t.co/7oajgLXB0B
Pharma's key drivers for 2014
In many ways, 2014 has kicked off in a very similar way to how 2013 started for the global pharmaceutical industry: with a major setback. In 2013, this came at the hands of the unexpected FDA non-approval of Novo Nordisk's new diabetes treatment Tresiba (insulin degludec) in the United States.
In 2014, the bad news came from Germany, where IQWiG's concluded that a trio of innovative treatments - Tafinlar (dabrafenib), Eylea (aflibercept) and Aubagio (terfilunomide) - provided no additional benefits in their respective health technology assessments (HTA). And even while reimbursement issues, drug shortages, and policy reforms continue to change and shape the industry it looks like 2014 may well be a road to economic recovery.
IHS Healthcare and Pharma offers a look at the trends and developments that will shape the industry in 2014.
Key drivers for 2014 1. The foundations for economic recovery continue to be in place 2. The United States' first full year of ACA 3. Europe/Eurozone instability will continue to suppress public health expenditure 4. Secondary emerging markets are expanding healthcare insurance 5. Reimbursement continues to offer a mixed picture 6. Patent expirations continue to be a significant driver, but it is a comparatively quiet year 7. IRP baskets continue to evolve 8. Drug shortages will continue, but clampdowns on parallel exports are seen in many countries 9. Price cuts in Japan - but some incentives for innovation 10. New technology developments
Click here to download more details about what to expect in 2014. We will dive deeply into a number of these ideas in the coming months here on the blog.
- Pfizer and BioNTech's COVID-19 vaccine
- Mixed news on COVID19 vaccines: COVID-19 R&D tracker
- Innovation in Japan’s regenerative sector
- US drug prices could be drastically impacted by Most Favored Nation executive order
- Global healthcare spend to remain stable
- The pandemic pricing dilemma: A COVID-19 vaccine at-cost or for profit?
- US school re-opening decisions in a pandemic environment are complex – data can help
- Trump resurrects International Reference Pricing (IRP) proposal on pharmaceuticals with executive order
Register from the latest on the progression of the pandemic and the future that lies ahead of us from our Vice Pres… https://t.co/GiqhM1V318
We are expecting major clinical readouts from several key COVID-19 vaccine and therapeutics candidates- our weekly… https://t.co/aIcNOmccrx